CD274 and urothelial carcinoma: Urgent novel treatment options other than standard cisplatin-based chemotherapy are needed for the treatment of this HS.45 Plasmacytoid urothelial carcinoma also does not appear to be a suitable candidate for ICI therapy due to frequently low PD-1/PD-L1 expression rates46